[Effect of PSK on prostaglandin metabolism (I)].
The effect of PSK (Krestin) on the metabolism of prostaglandins was investigated. The effect of PSK on the thromboxane A2 (TXA2) level, which stimulates tumor proliferation and platelet aggregation, was examined using platelets. PSK suppressed platelet aggregation and the production of malondialdehyde (MDA) and TXB2 which is a stable metabolite of TXA2. The effect of PSK on the production of prostacyclin (PGI2), which is an anti-tumor PG, was then examined using rat arterial rings. It was found that PGI2 production was stimulated by PSK. The in vivo inhibition of platelet activation by PSK was then examined using two thrombosis models in which platelet aggregation was mainly involved. PSK exerted its anti-platelet effect by regulation of PG production. It was concluded that not only an immune regulating effect but also PG regulation are involved in the pharmacological action of PSK.
D000818:Animals; D011464:Epoprostenol / Q000096:biosynthesis; D006801:Humans; D066298:In Vitro Techniques; D008297:Male; D008315:Malondialdehyde / Q000378:metabolism; D051379:Mice; D010974:Platelet Aggregation; D011453:Prostaglandins / Q000378:metabolism*; D011509:Proteoglycans / Q000494:pharmacology*; D011655:Pulmonary Embolism / Q000188:drug therapy; D011817:Rabbits; D051381:Rats; D011919:Rats, Inbred Strains; D012772:Shock, Septic / Q000188:drug therapy; D013928:Thromboxane A2 / Q000097:blood; D013929:Thromboxane B2 / Q000097:blood
D011453:Prostaglandins; D011509:Proteoglycans; C010770:polysaccharide-K; D008315:Malondialdehyde; D013929:Thromboxane B2; D013928:Thromboxane A2; D011464:Epoprostenol